Porton and Dragon Sail Forge Groundbreaking ADC Partnership

On December 20, 2024, Porton Pharma Solutions Ltd. (“Porton”) and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (“Dragon Sail Pharmaceutical”), a subsidiary of Guilin Sanjin, took a significant step toward transforming the antibody-drug conjugate (ADC) landscape. The two companies officially entered into a strategic partnership, signing an agreement in Guilin, China. The collaboration aims to integrate their expertise in research, development, production, and supply chain management to streamline the ADC development process.

Present at the ceremony were Mr. Ju Nianfeng, Chairman and CEO of Porton Pharma Solutions; Mr. Zou Xun, Chairman of Guilin Sanjin; and Mr. Tan Kai, General Manager of Dragon Sail Pharmaceutical.

Combining Strengths to Revolutionize ADC Development

Porton Pharma Solutions, a global leader in end-to-end CDMO services, offers advanced technology platforms and deep experience in producing small molecules, peptides, oligonucleotides, and ADCs. Meanwhile, Dragon Sail Pharmaceutical specializes in biological drugs like monoclonal antibodies and fusion proteins.

This partnership will combine their resources and technical capabilities to establish a one-stop service for ADC drugs, encompassing:

• Development and manufacturing of bulk drug substances and finished products.
• End-to-end support, from early development to large-scale commercial production.
• Optimized timelines and improved delivery efficiency to strengthen market competitiveness.

By working together, the companies aim to create more efficient solutions, reduce ADC development times, and deliver innovative therapies to global markets faster.

Voices from Leadership

At the signing ceremony, Mr. Oliver (Nianfeng) Ju, Chairman and CEO of Porton Pharma Solutions, highlighted the broader impact of this partnership:
“This collaboration represents more than just business growth; it reflects a shared commitment to advancing the pharmaceutical industry. By combining Porton’s ADC expertise with Dragon Sail Pharmaceutical’s biological drug strengths, we are paving the way for new innovations that will improve lives worldwide.”

Mr. Zou Xun, Chairman of Guilin Sanjin, emphasized the importance of their shared vision:
“This partnership goes beyond integrating our capabilities. It is about driving forward ADC drug development to bring better medicines to those who need them.”

A Vision for the Future

Both companies have identified Shanghai Waigaoqiao (Porton) and Shanghai Lingang (White Sail) as strategic hubs to foster innovation and growth. By uniting resources and embracing cutting-edge technology, Porton and Dragon Sail aim to build a sustainable and impactful global pharmaceutical ecosystem.

Their ultimate goal is clear: to enable faster access to life-changing medicines while driving the rapid and healthy advancement of the ADC industry worldwide.